VX-765, an orally available caspase-1 inhibitor, demonstrated acceptable safety profiles in phase II epilepsy trials and shows promise for reducing IL-1β-mediated inflammation in COPD (97). This evidence concerns the gene CASP1 and chronic obstructive pulmonary disease.